Analyst Price Targets — ZLAB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 1:17 pm | — | UBS | $35.00 | $19.00 | TheFly | Zai Lab initiated with a Buy at UBS |
| June 30, 2025 5:43 pm | — | Leerink Partners | $75.00 | $34.97 | TheFly | Zai Lab price target raised to $75 from $73 at Leerink |
| March 7, 2025 11:46 am | — | Scotiabank | $55.00 | $36.42 | TheFly | Zai Lab initiated with an Outperform at Scotiabank |
| September 27, 2024 8:05 am | Jack Lin | Morgan Stanley | $50.00 | $23.63 | StreetInsider | Morgan Stanley on Zai Lab (ZLAB) Post BMY (BMY) Approval: 'We believe it should bode moderately positively for ZLAB shares' |
| April 21, 2022 11:15 am | — | Leerink Partners | $101.00 | $42.88 | Benzinga | SVB Leerink Maintains Outperform on Zai Lab, Lowers Price Target to $101 |
Latest News for ZLAB
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of pulmonary neuroendocrine carcinomas (NECs). The…
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has approved the Biologics License Application (BLA) for TIVDAK® (tisotumab vedotin for injection) for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This approval is based…
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced changes to its senior leadership team aimed at strengthening operational performance and efficiency. As part of these changes, the Board has made the decision that Josh Smiley, President and COO, will no longer be with the Company, effective Friday, May 22. "I want to thank Josh for his contributions to Zai Lab…
Zai Lab faces stalling growth in Greater China due to price controls and declining Zejula revenues, shifting focus to global pipeline assets. I assign zero intrinsic value to ZLAB's China business, given minimal "bottom line" contributions from blockbuster launches like Vyvgart and anticipated similar outcomes for KarXT. Zoci, a wholly owned Phase 3 oncology asset, is the key value driver for the company, with a…
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to zocilurtatug pelitecan (zoci, formerly ZL-1310), the Company's potential first-in-class Delta-like ligand 3 (DLL3)-targeting antibody-drug conjugate (ADC), for the treatment of extrapulmonary neuroendocrine carcinomas (epNECs)…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ZLAB.
U.S. House Trading
No House trades found for ZLAB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.